Performance of a novel Next Generation Sequencing circulating tumor DNA (ctDNA) platform for the evaluation of samples from patients with metastatic breast cancer (MBC).
Circulating tumor DNA
Clinical utility
Next generation sequencing
Precision medicine
Journal
Critical reviews in oncology/hematology
ISSN: 1879-0461
Titre abrégé: Crit Rev Oncol Hematol
Pays: Netherlands
ID NLM: 8916049
Informations de publication
Date de publication:
Jan 2020
Jan 2020
Historique:
received:
17
06
2019
revised:
25
10
2019
accepted:
02
12
2019
pubmed:
31
12
2019
medline:
18
2
2020
entrez:
30
12
2019
Statut:
ppublish
Résumé
Circulating tumor DNA (ctDNA) is gaining momentum as sensitive diagnostic tool for advanced disease characterization because of its ability both to capture the tumor's heterogeneity and its dynamic adaptations. However, the consistency between all the available platforms is still debated. The aim of the study was to explore the performance of the novel diagnostic NGS platform PredicinePLUS™ and to compare its results with the clinically available Guardant360™ platform for possible analytical inconsistencies. The study suggests that PredicinePLUS™ NGS platform can detect genomic alterations and measure allele frequency in samples of MBC patients and confirmed that different NGS platforms could be potentially compared provided that certain sample management and analytical requirements are met.
Identifiants
pubmed: 31884205
pii: S1040-8428(19)30242-2
doi: 10.1016/j.critrevonc.2019.102856
pii:
doi:
Substances chimiques
Biomarkers, Tumor
0
Circulating Tumor DNA
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
102856Informations de copyright
Copyright © 2019 Elsevier B.V. All rights reserved.